GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Cyclically Adjusted Price-to-FCF

Immunovia AB (OSTO:IMMNOV) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunovia AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Immunovia AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Cyclically Adjusted Price-to-FCF Chart

Immunovia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunovia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovia AB's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Immunovia AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Immunovia AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Immunovia AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Immunovia AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.101/132.8245*132.8245
=-0.101

Current CPI (Mar. 2025) = 132.8245.

Immunovia AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 100.225 0.000
201506 0.000 99.995 0.000
201512 0.000 100.276 0.000
201603 -0.260 100.751 -0.343
201606 -0.289 101.019 -0.380
201609 -0.310 101.138 -0.407
201612 -0.435 102.022 -0.566
201703 -0.349 102.022 -0.454
201706 -0.508 102.752 -0.657
201709 -0.497 103.279 -0.639
201712 -0.752 103.793 -0.962
201803 -0.657 103.962 -0.839
201806 -0.810 104.875 -1.026
201809 -0.786 105.679 -0.988
201812 -0.758 105.912 -0.951
201903 -0.583 105.886 -0.731
201906 -0.745 106.742 -0.927
201909 -0.931 107.214 -1.153
201912 -0.769 107.766 -0.948
202003 -0.922 106.563 -1.149
202006 -0.857 107.498 -1.059
202009 -0.903 107.635 -1.114
202012 -0.948 108.296 -1.163
202103 -0.865 108.360 -1.060
202106 -0.864 108.928 -1.054
202109 -0.838 110.338 -1.009
202112 -1.035 112.486 -1.222
202203 -1.024 114.825 -1.185
202206 -0.918 118.384 -1.030
202209 -0.823 122.296 -0.894
202212 -0.859 126.365 -0.903
202303 0.077 127.042 0.081
202306 -0.518 129.407 -0.532
202309 -0.837 130.224 -0.854
202312 -0.629 131.912 -0.633
202403 -0.539 132.205 -0.542
202406 -0.293 132.716 -0.293
202409 -0.247 132.304 -0.248
202412 -0.167 132.987 -0.167
202503 -0.101 132.825 -0.101

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunovia AB  (OSTO:IMMNOV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Immunovia AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines